Krystal Biotech, Inc. (KRYS)
303.49
-2.19
(-0.72%)
USD |
NASDAQ |
Nov 13, 10:38
Krystal Biotech Gross Profit Margin (Quarterly) : 92.91% for Sept. 30, 2026
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 92.91% |
| June 30, 2026 | 93.46% |
| March 31, 2026 | 93.26% |
| December 31, 2025 | 92.39% |
| September 30, 2025 | 94.21% |
| June 30, 2025 | 90.93% |
| March 31, 2025 | 92.45% |
| Date | Value |
|---|---|
| December 31, 2024 | 92.83% |
| September 30, 2024 | 90.25% |
| June 30, 2024 | 88.62% |
| March 31, 2024 | 91.10% |
| December 31, 2023 | 89.61% |
| September 30, 2023 | 83.37% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| Alnylam Pharmaceuticals, Inc. | 75.19% |
| Ionis Pharmaceuticals, Inc. | 95.39% |
| Ultragenyx Pharmaceutical, Inc. | 76.30% |
| BridgeBio Pharma, Inc. | 94.11% |
| Cytokinetics, Inc. | 87.67% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | 17.51% |
| Return on Assets | 15.95% |
| Return on Invested Capital | 17.39% |
| Profit Margin (Quarterly) | 49.53% |
| Operating Margin (Quarterly) | 55.87% |
| Return on Net Operating Assets | 65.23% |